For Corporates
Analyzing Healthcare M&A Trends: Q1 2024 Insights
Healthcare M&A activity remained robust in the first quarter of 2024, with 29 transactions vs. 28 in 2023. Biopharma was the most active healthcare subsector, representing 45% of deal volume, while Services activity remained dampened despite notable transactions such as Novo Holdings’ acquisition of Catalent. We expect Biopharma M&A activity to remain robust as large pharmaceutical companies attempt to fill revenue and pipeline gaps via acquisitions of late- or commercial-stage companies. We expect pre-commercial biopharma companies to continue pursue strategic alternatives, including mergers, private company mergers and cash-out transactions as a result of the dynamic capital markets environment.
LEARN MORE
For Investors
Sectors
Insights
About
- Firm
- Careers
- News
- Contact
- Transactions

CPE Contact

Our team looks forward to connecting with you. Complete the form below to get added to our mailing list or inquire about collaborative and consultative opportunities. “*” indicates required fields

First Name(Required)

Last Name(Required)

Email(Required)

Company Name(Required)

Title(Required)

Business Sector(Required)

Inquiry(Required)

Message

Comments

This field is for validation purposes and should be left unchanged.

CPE Contact

Join Our Mailing List

CPE Contact